Identification of Targets for Subsequent Treatment of Crohn’s Disease Patients After Failure of Anti-TNF Therapy

References

• Roda G, Chien Ng S, Kotze PG, et al. Crohn’s disease. Nat Rev Dis Primers. 2020;6(1):22. doi:10.1038/s41572-020-0156-2
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106. doi:10.1136/gutjnl-2019-318484
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn’s disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol. 2013;10(6):345–351. doi:10.1038/nrgastro.2013.31
   PubMed Web of Science ®Google Scholar
• Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505. doi:10.1136/bmj.j2505
   PubMed Web of Science ®Google Scholar
• C RGM, Chaparro M, Mesonero F, et al. Effectiveness of anti-TNFalpha drugs in patients with Crohn’s disease who do not achieve remission with their first anti-TNFalpha agent. Dig Liver Dis. 2016;48(6):613–619. doi:10.1016/j.dld.2016.02.012
   Google Scholar
• Gisbert JP, Chaparro M. Primary failure to an anti-tnf agent in inflammatory bowel disease: switch (to a Second Anti-TNF Agent) or Swap (for another mechanism of action)? J Clin Med. 2021;10(22):5318. doi:10.3390/jcm10225318
   PubMed Web of Science ®Google Scholar
• Liefferinckx C, Minsart C, Cremer A, et al. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. Eur J Gastroenterol Hepatol. 2019;31(4):478–485. doi:10.1097/MEG.0000000000001356
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627 e613. doi:10.1053/j.gastro.2014.05.008
   PubMed Web of Science ®Google Scholar
• Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685–698. doi:10.1038/ajg.2011.103
   PubMed Web of Science ®Google Scholar
• Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and bioConductor. Bioinformatics. 2007;23(14):1846–1847. doi:10.1093/bioinformatics/btm254
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Kolde R, Laur S, Adler P, Vilo J. Robust rank aggregation for gene list integration and meta-analysis. Bioinformatics. 2012;28(4):573–580. doi:10.1093/bioinformatics/btr709
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9:559. doi:10.1186/1471-2105-9-559
   PubMed Web of Science ®Google Scholar
• The Gene Ontology C. The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47(D1):D330–D338. doi:10.1093/nar/gky1055
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353–D361. doi:10.1093/nar/gkw1092
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–d613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(4):S11. doi:10.1186/1752-0509-8-S4-S11
   PubMedGoogle Scholar
• Gorelik Y, Freilich S, Gerassy-Vainberg S, et al. Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFalpha therapy in inflammatory bowel disease patients: a report from the epi-IIRN. Gut. 2022;71(2):287–295. doi:10.1136/gutjnl-2021-325185
   Web of Science ®Google Scholar
• Reichel CA, Puhr-Westerheide D, Zuchtriegel G, et al. C-C motif chemokine CCL3 and canonical neutrophil attractants promote neutrophil extravasation through common and distinct mechanisms. Blood. 2012;120(4):880–890. doi:10.1182/blood-2012-01-402164
   PubMed Web of Science ®Google Scholar
• Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. Febs j. 2018;285(16):2944–2971. doi:10.1111/febs.14466
   PubMed Web of Science ®Google Scholar
• Ramos CD, Canetti C, Souto JT, et al. MIP-1alpha[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-alpha and LTB4. J Leukoc Biol. 2005;78(1):167–177. doi:10.1189/jlb.0404237
   PubMed Web of Science ®Google Scholar
• Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn’s disease. J Pathol. 2003;199(1):28–35. doi:10.1002/path.1245
   PubMed Web of Science ®Google Scholar
• Boro M, Balaji KN. CXCL1 and CXCL2 Regulate NLRP3 Inflammasome Activation via G-Protein-Coupled Receptor CXCR2. J Immunol. 2017;199(5):1660–1671. doi:10.4049/jimmunol.1700129
   PubMed Web of Science ®Google Scholar
• De Filippo K, Dudeck A, Hasenberg M, et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood. 2013;121(24):4930–4937. doi:10.1182/blood-2013-02-486217
   PubMed Web of Science ®Google Scholar
• Sawant KV, Sepuru KM, Lowry E, et al. Neutrophil recruitment by chemokines Cxcl1/KC and Cxcl2/MIP2: role of Cxcr2 activation and glycosaminoglycan interactions. J Leukoc Biol. 2021;109(4):777–791. doi:10.1002/JLB.3A0820-207R
   Web of Science ®Google Scholar
• Arijs I, De Hertogh G, Machiels K, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol. 2011;106(4):748–761. doi:10.1038/ajg.2011.27
   Web of Science ®Google Scholar
• Cripps JG, Celaj S, Burdick M, Strieter RM, Gorham JD. Liver inflammation in a mouse model of Th1 hepatitis despite the absence of invariant NKT cells or the Th1 chemokine receptors CXCR3 and CCR5. Lab Invest. 2012;92(10):1461–1471. doi:10.1038/labinvest.2012.104
   Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Colombel JF, et al. Eldelumab [anti-interferon-gamma-inducible protein-10 antibody] induction therapy for active crohn’s disease: a randomised, double-blind, placebo-controlled phase iia study. J Crohns Colitis. 2017;11(7):811–819. doi:10.1093/ecco-jcc/jjx005
   PubMed Web of Science ®Google Scholar
• Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019;50(4):992–1006. doi:10.1016/j.immuni.2019.03.017
   PubMed Web of Science ®Google Scholar
• Bank S, Julsgaard M, Abed OK, et al. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(7):890–903. doi:10.1111/apt.15187
   PubMed Web of Science ®Google Scholar
• Bank S, Andersen PS, Burisch J, et al. Associations between functional polymorphisms in the NFkappaB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14(6):526–534. doi:10.1038/tpj.2014.19
   PubMed Web of Science ®Google Scholar
• Martin JC, Chang C, Boschetti G, et al. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to Anti-TNF therapy. Cell. 2019;178(6):1493–1508 e1420. doi:10.1016/j.cell.2019.08.008
   PubMed Web of Science ®Google Scholar
• Devlin JC, Axelrad J, Hine AM, et al. Single-cell transcriptional survey of ileal-anal pouch immune cells from ulcerative colitis patients. Gastroenterology. 2021;160(5):1679–1693. doi:10.1053/j.gastro.2020.12.030
   Web of Science ®Google Scholar
• Dosh RH, Jordan-Mahy N, Sammon C, Le Maitre C. Interleukin 1 is a key driver of inflammatory bowel disease-demonstration in a murine IL-1Ra knockout model. Oncotarget. 2019;10(37):3559–3575. doi:10.18632/oncotarget.26894
   Google Scholar
• Soderman J, Berglind L, Almer S. Gene expression-genotype analysis implicates GSDMA, GSDMB, and LRRC3C as Contributors to inflammatory bowel disease susceptibility. Biomed Res Int. 2015;2015:834805. doi:10.1155/2015/834805
   Web of Science ®Google Scholar
• Shi YJ, Hu SJ, Zhao QQ, Liu XS, Liu C, Wang H. Toll-like receptor 4 (TLR4) deficiency aggravates dextran sulfate sodium (DSS)-induced intestinal injury by down-regulating IL6, CCL2 and CSF3. Ann Transl Med. 2019;7(23):713. doi:10.21037/atm.2019.12.28
   Web of Science ®Google Scholar
• Prins MM, Verstockt B, Ferrante M, Vermeire S, Wildenberg ME, Koelink PJ. Monocyte TREM-1 levels associate with anti-TNF Responsiveness in IBD through autophagy and fcgamma-receptor signaling pathways. Front Immunol. 2021;12:627535. doi:10.3389/fimmu.2021.627535
   PubMed Web of Science ®Google Scholar
• Caer C, Gorreja F, Forsskahl SK, et al. TREM-1+ macrophages define a pathogenic cell subset in the intestine of Crohn’s disease patients. J Crohns Colitis. 2021;15(8):1346–1361. doi:10.1093/ecco-jcc/jjab022
   PubMed Web of Science ®Google Scholar
• Danese S, Vermeire S, Hellstern P, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2019;68(1):40–48. doi:10.1136/gutjnl-2017-314562
   PubMed Web of Science ®Google Scholar
• Leal RF, Planell N, Kajekar R, et al. Identification of inflammatory mediators in patients with Crohn’s disease unresponsive to anti-TNFalpha therapy. Gut. 2015;64(2):233–242. doi:10.1136/gutjnl-2013-306518
   Web of Science ®Google Scholar
• Dahlqvist J, Fulco CP, Ray JP, et al. Systematic identification of genomic elements that regulate FCGR2A expression and harbor variants linked with autoimmune disease. Hum Mol Genet. 2022;31(12):1946–1961. doi:10.1093/hmg/ddab372
   Web of Science ®Google Scholar
• Castro-Dopico T, Dennison TW, Ferdinand JR, et al. Anti-commensal IgG drives intestinal inflammation and type 17 immunity in ulcerative colitis. Immunity. 2019;50(4):1099–1114 e1010. doi:10.1016/j.immuni.2019.02.006
   PubMed Web of Science ®Google Scholar